CLSDQ Clearside Biomedical (CLSDQ) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001539029
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Clearside Biomedical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Clearside Biomedical, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-79.8% year over year
below 87% of Pharma & Biotech
Margin
-2064.4% net margin
below 92% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CLSDQ
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns CLSDQ: institutional holders (13F)
13F holdings, latest reported quarter
27,136 sh
$3.3K
Congress trades in CLSDQ
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CLSDQ planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
1
Not applicable
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.3M
$1.1M
$947.2K
-65%
n/a
2023
$1.5M
$1.3M
$609.0K
-57%
n/a
2022
$1.5M
$425.0K
$906.2K
-59%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
CLSDQ financials
Revenue growth
-79.8%
XBRL, annual
Net margin
-2064.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.3M
four quarters, 2024-10-01 to 2025-09-30
Revenue, TTM CLSDQ
| FY Dec 2024 | $1.7M |
| FY Dec 2023 | $8.2M |
| FY Dec 2022 | $1.3M |
| FY Dec 2021 | $29.6M |
| FY Dec 2020 | $7.9M |
| Sep 2025 | $201.0K |
| Jun 2025 | $492.0K |
| Mar 2025 | $2.3M |
| Dec 2024 | $306.0K |
| Sep 2024 | $1.0M |
| Jun 2024 | $90.0K |
| Mar 2024 | $230.0K |
| Dec 2023 | $6.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-780.9%
net income over revenue, 2024-10-01 to 2025-09-30
Net margin, TTM CLSDQ
| FY Dec 2024 | -2,064% |
| FY Dec 2023 | -394.9% |
| FY Dec 2022 | -2,483% |
| FY Dec 2021 | +1.3% |
| FY Dec 2020 | -230.7% |
| Sep 2025 | n/a |
| Jun 2025 | -913.6% |
| Mar 2025 | -352.9% |
| Dec 2024 | -2,388% |
| Sep 2024 | -740.7% |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | -76.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$21.7M
operating cash flow minus capex, 2024-10-01 to 2025-09-30
Free cash flow, TTM CLSDQ
| FY Dec 2024 | -$25.7M |
| FY Dec 2023 | -$19.9M |
| FY Dec 2022 | -$13.6M |
| FY Dec 2021 | -$10.8M |
| FY Dec 2020 | -$13.2M |
| Sep 2025 | -$5.5M |
| Jun 2025 | -$4.7M |
| Mar 2025 | -$5.8M |
| Dec 2024 | -$5.7M |
| Sep 2024 | -$6.0M |
| Jun 2024 | -$6.1M |
| Mar 2024 | -$7.9M |
| Dec 2023 | $375.0K |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | 0.04x |
| FY Dec 2020 | 0.16x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-15.47x
TTM operating cash flow over long-term 2020-09-30 (60 months older than the period end) plus current 2020-12-31 (57 months older than the period end)
Cash flow to debt CLSDQ
| FY Dec 2024 | -17.95x |
| FY Dec 2023 | -13.18x |
| FY Dec 2022 | -9.71x |
| FY Dec 2021 | -7.80x |
| FY Dec 2020 | -9.53x |
| Sep 2025 | -15.47x |
| Jun 2025 | -15.79x |
| Mar 2025 | -16.48x |
| Dec 2024 | -17.95x |
| Sep 2024 | -13.77x |
| Jun 2024 | -13.89x |
| Mar 2024 | -13.64x |
| Dec 2023 | -13.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -135.6% |
| FY Dec 2021 | +1.6% |
| FY Dec 2020 | -182.8% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-127.4%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on assets CLSDQ
| FY Dec 2024 | -116.2% |
| FY Dec 2023 | -76.1% |
| FY Dec 2022 | -69.9% |
| FY Dec 2021 | +1.2% |
| FY Dec 2020 | -79.0% |
| Sep 2025 | -127.4% |
| Jun 2025 | -112.5% |
| Mar 2025 | -103.0% |
| Dec 2024 | -116.2% |
| Sep 2024 | -100.3% |
| Jun 2024 | -91.5% |
| Mar 2024 | -82.4% |
| Dec 2023 | -76.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-141.6%
operating income (EBIT proxy) over average of 2024-09-30 and 2025-09-30 minus current liabilities
Return on capital employed CLSDQ
| FY Dec 2024 | -121.5% |
| FY Dec 2023 | -68.3% |
| FY Dec 2022 | -72.3% |
| FY Dec 2021 | -2.6% |
| FY Dec 2020 | -142.0% |
| Sep 2025 | -141.6% |
| Jun 2025 | -108.3% |
| Mar 2025 | -106.0% |
| Dec 2024 | -121.5% |
| Sep 2024 | -94.5% |
| Jun 2024 | -83.2% |
| Mar 2024 | -68.9% |
| Dec 2023 | -68.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
no close on file at or before the as-of date
P/E, trailing CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
no close on file at or before the as-of date
PEG, trailing CLSDQ
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
| Dec 2023 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2024-12 | 2023-12 | 2022-12 | 2021-12 | |
|---|---|---|---|---|
| Revenue | $1.7M | $8.2M | $1.3M | $29.6M |
| Operating income | -$28.9M | -$24.8M | -$30.3M | -$627.0K |
| Net income | -$34.4M | -$32.5M | -$32.9M | $376.0K |
| EPS (diluted) | -0.47 | -0.53 | -0.55 | 0.01 |
| Operating cash flow | -$24.7M | -$18.1M | -$13.4M | -$10.7M |
| Cash | $20.0M | $28.9M | $48.3M | $30.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
CLSDQ Stock Sonar score 3/7 axes
Find similar shapesCompareCLSDQ ranks highest on financial health (20th percentile) and profitability (18th), and lowest on growth (13th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
